Accelerating Custom Antibody Development for Immune Cell Therapy
Immune cell therapies demand fast, flexible development of high-quality reagents—especially recombinant antibodies critical to early-stage innovation. This application note highlights how R&D Systems enabled the rapid discovery, development, and scale-up of a unique TNFR-targeting antibody in just 12 weeks. By leveraging a proprietary hybridoma library, the TcBuster™ transposon system, and GMP-compliant manufacturing workflows, R&D Systems delivered a functionally validated, preclinical-grade antibody tailored for immune cell therapy. From initial screening to large-scale production, the process ensured consistency, scalability, and speed—key for next-gen ICT development. Discover how this integrated end-to-end platform supports accelerated timelines without compromising quality, giving developers a clear path from concept to clinic.
